Solid Q2 21 was largely expected
21/07/21 -"Sartorius Stedim’s Q2/H1 21 earnings had little element of surprise following the preliminary announcement on 6 July. H1 sales (+61.1%), EBITDA margin (36.1%) as well as guidance (FY21 top line +48%, ..."
Pages
69
Language
English
Published on
21/07/21
You may also be interested by these reports :
29/07/26
bioMerieux’s H1 profitability largely met expectations. Q2 sales growth was driven by increases across both segments, supported by its GO28 growth ...
28/07/26
Philips’ Q2 sales surpassed expectations, with profitability excluding one-offs meeting forecasts. The 2026 guidance was reaffirmed. However, ...
24/07/26
Sartorius reported mixed Q2 26 numbers, with revenue below consensus (-2.3%) but underlying EBITDA slightly ahead (+0.5%). Equipment inflected as ...
23/07/26
Sartorius Stedim Biotech reported mixed Q2 26 numbers, with revenue below consensus (-2.8%) but underlying EBITDA ahead (+1.1%). The miss is largely ...